Verition Fund Management’s BioNTech BNTX Stock Holding History

Verition Fund Management’s Portfolio BNTX Stock Details BNTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$433K	Sell	4,658 -468	-9%	-$44K	﹤0.01%	1675
2026 Q1	$456K	Sell	5,126 -2,364	-32%	-$243K	﹤0.01%	1621
2025 Q4	$713K	Sell	7,490 -4,652	-38%	-$469K	﹤0.01%	2408
2025 Q3	$1.2M	Buy	+12,142	New	+$1.3M	﹤0.01%	2391
2025 Q1	–	Sell	-16,951	Closed	-$1.93M	–	3348
2024 Q4	$1.93M	Buy	+16,951	New	+$1.93M	0.01%	1575
2022 Q1	–	Sell	-894	Closed	-$230K	–	2737
2021 Q4	$230K	Buy	+894	New	+$245K	﹤0.01%	2157
2021 Q1	–	Sell	-6,456	Closed	-$526K	–	1554
2020 Q4	$526K	Buy	+6,456	New	+$634K	﹤0.01%	660

Other funds holding BNTX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Flossbach Von Storch Cologne, Germany $22.1B AUM 6.81% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

GSK plc London $602M AUM

Verition Fund Management's BNTX Position: Q2 2026 in Review

Verition Fund Management reduced its BioNTech (BNTX) stake by 9.1% in Q2 2026, selling an estimated $44K and leaving 4,658 shares worth $433K. The position accounts for ﹤0.01% of the portfolio, ranked #1675.

Verition Fund Management first reported a position in BNTX in Q4 2020 and has held it in 7 quarters since. The position peaked at $1.93M in Q4 2024. 282 funds tracked by Wall St. Rank hold BNTX as of Q2 2026.

Verition Fund Management held 4,658 shares of BioNTech worth $433K as of Q2 2026.
Verition Fund Management sold 468 BioNTech shares in Q2 2026, an estimated $44K.
BioNTech made up ﹤0.01% of Verition Fund Management's portfolio in Q2 2026, its #1675 holding.
Verition Fund Management first reported a position in BioNTech in Q4 2020 and has held it in 7 quarters since.
Verition Fund Management's BioNTech position peaked at $1.93M in Q4 2024.
282 funds tracked by Wall St. Rank held BioNTech as of Q2 2026.

Based on Verition Fund Management's 13F filing for Q2 2026, filed 14 Aug 2026.